TMS For When Drugs Don’t Work For Depression
Posted On June 9, 2020
Most people with depression are likely to receive Antidepressants as a first treatment when visiting their doctor for help. While this isn’t ideal, it is sometimes the only option available as long waiting lists along with a lack of resources means that other types of therapies like cognitive therapy may not be available immediately. Read more on FLORIDA TMS CLINIC.
Although antidepressants are effective for many, any relief they offer comes with the price of suffering some unpleasant side effects, including nausea , dizziness, sleep disturbances, headaches, loss of libido, agitation, and erectile dysfunction in men. Another issue is that in some people antidepressants will have no effect whatsoever on the symptoms of depression. No one really knows why this is the case, and projecting which people will benefit and which won’t.
Now, a recent study has highlighted a groundbreaking intervention that is quickly gaining attention as a potential maintenance treatment for major depression in patients that either couldn’t take antidepressants or felt the antidepressant drugs didn’t work.
Transcranial magnetic stimulation, or TMS as it is known, is a treatment that involves magnets placed on the head to send magnetic pulses to the parts of the brain that regulate mood.
The company that developed TMS machine that apparently carries very few side effects, if any. After treatment the most common is mild headache.
In a pilot study conducted by Neurostar, the researchers treated half of the TMS patients for a six-week period, and the other half were observed monthly. They found that 61.2 percent of those treated with TMS had experienced a remission of symptoms of depression after the six-week period, and after three months the figure was 62.5 percent compared to 43.8 percent of those who did not receive TMS therapy.
“This pilot study supports the notion that maintenance TMS can be useful in preventing major depression recurrence and is an important step in learning what the optimum treatment parameters will be,” Dr. Scott Aaronson, Director of Clinical Research Programs and Associate Medical Director at Sheppard Pratt, said in a statement.
“This new information will help describe a TMS strategy as a maintenance therapy while we expand our knowledge of TMS ‘s long-term effectiveness in treating people with this debilitating disease.”
Inc. announced their study results at the 167th Annual Meeting of the American Psychiatric Association in New York. The treatment is safe according to the firm.